Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2): A follow‐up study
Open Access
- 2 November 2022
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 30 (2), 463-473
- https://doi.org/10.1111/ene.15602
Abstract
Background and purpose Population-based studies suggest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may trigger neurological autoimmunity including immune-mediated thrombotic thrombocytopenia. Long-term characterization of cases is warranted to facilitate patient care and inform vaccine-hesitant individuals. Methods In this single-center prospective case study with a median follow-up of 387 days long-term clinical, laboratory and imaging characteristics of patients with neurological autoimmunity diagnosed in temporal association (<= 6 weeks) with SARS-CoV-2 vaccinations are reported. Results Follow-up data were available for 20 cases (central nervous system demyelinating diseases n = 8, inflammatory peripheral neuropathies n = 4, vaccine-induced immune thrombotic thrombocytopenia n = 3, myositis n = 2, myasthenia n = 1, limbic encephalitis n = 1, giant cell arteritis n = 1). Following therapy, the overall disability level improved (median modified Rankin Scale at diagnosis 3 vs. 1 at follow-up). The condition of two patients worsened despite immunosuppressants possibly related to their autoimmune diagnoses (limbic encephalitis n = 1, giant cell arteritis n = 1). At 12 months' follow-up, 12 patients achieved complete clinical remissions with partial responses in five and stable disease in one case. Correspondingly, autoimmune antibodies were non-detectable or titers had significantly lowered in all, and repeat imaging revealed radiological responses in most cases. Under vigilant monitoring 15 patients from our cohort underwent additional SARS-CoV-2 vaccinations (BNT162b2 n = 12, mRNA-1273 n = 3). Most patients (n = 11) received different vaccines than prior to diagnosis of neurological autoimmunity. Except for one short-lasting relapse, which responded well to steroids, re-vaccinations were well tolerated. Conclusions In this study long-term characteristics of neurological autoimmunity encountered after SARS-CoV-2 vaccinations are defined. Outcome was favorable in most cases. Re-vaccinations were well tolerated and should be considered on an individual risk/benefit analysis.Keywords
This publication has 56 references indexed in Scilit:
- Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large seriesBMC Neurology, 2013
- Assessment of Outcome Predictors in First-Episode Acute MyelitisArchives of Neurology, 2010
- Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet Neurology, 2008
- Multiple Sclerosis Risk After Optic NeuritisArchives of Neurology, 2008
- Predictors of Outcome in Patients With Cerebral Venous Thrombosis and Intracerebral HemorrhageStroke, 2007
- Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patientsJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Visual Function 5 Years After Optic NeuritisAmerican Journal of Ophthalmology, 1997
- Optic Neuritis Treatment TrialAmerican Journal of Ophthalmology, 1993
- Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disordersZeitschrift für Neurologie, 1986